APhA announces candidates for 2015-2016 president-elect; group awards grants for pharmacy-based projects to improve care
WASHINGTON — A pharmacy professor and compounding pharmacy owner are candidates for president-elect of the American Pharmacists Association for 2015-2016, the group said.
The APhA said the candidates for the position are Virginia Commonwealth University School of Pharmacy professor and community pharmacy residency program director Jean-Venable Goode and Newport Beach, Calif.-based Westcliff Compounding Pharmacy owner Michael Pavlovich. Members will have the opportunity to meet the candidates at the APhA Annual Meeting and Exposition in Orlando, Fla., in March.
Candidates for the APhA Board of Trustees for 2015-2018 are Daniel Buffington, Tampa, Fla.; Dennis Helling, Denver; Robert Greenwood, Waterloo, Iowa; and Linda Garrelts MacLean, Spokane, Wash. Metta Lou Henderson of Tucson, Ariz., is running unappeased for honorary president.
In addition, the APhA Foundation announced the 2014 recipients of its Incentive Grants for Practitioner Innovation in Pharmaceutical Care, which offers pharmacists seed money to implement or support innovative patient care services within their pharmacy practice. The recipients are:
- Student innovation in immunization practices, $1,000: Cassandra Song, Washington State University College of Pharmacy, Spokane, Wash.
- Practitioner innovation in immunization practices, $1,000: Donna Montemayor of H-E-B Pharmacy in San Antonio and Brenna Neumann of Collier Drug Stores in Fayetteville, Ark.
- Residents and their preceptors, $1,000: Vaidehi Bhatt, Walgreens, Cleveland, Texas; Courtney Bradley, Kroger Pharmacy, Cincinnati; Kendra Butler, Price Chopper Pharmacy, Overland Park, Kan.; Benjamin Culpepper, Kerr Drug and University of North Carolina Eshelman School of Pharmacy, Chapel Hill, N.C.; Tracy Frame, Rocking Horse Center, Springfield, Ohio; Charles Frye, Brame Huie Pharmacy, North Wilkesboro, N.C.
In addition, eight pharmacists from around the country received awards under the residents and their preceptors category for coordinated efforts between rural hospitals and community pharmacies to reduce readmission rates for high-risk patients, having submitted projects that studied such topics as medication synchronization and medication adherence efforts.
Bi-Lo, Winn-Dixie offer prescriptions at no upfront cost to insurance marketplace enrollees
GREENVILLE, S.C. — Bi-Lo and Winn-Dixie will cover initial prescription costs for customers who have enrolled in the health insurance marketplaces, but who don’t yet have their identification cards, the chains said.
The supermarket chains, both banners owned by Bi-Lo Holdings, will offer 30-day supplies of most prescription drugs at no upfront cost to health insurance marketplace enrollees until Jan. 31.
"Many of our customers need their prescriptions immediately and without interruption," Bi-Lo VP pharmacy John Fegan said. "By filling certain prescriptions at no upfront cost for up to 30 days, we hope to help make their transition to the public health insurance marketplace a little easier."
Customers hoping to receive the benefit must provide proof of enrollment, such as an email, letter or temporary identification card.
Canada’s Jean Coutu Group posts Q3 results
LONGUEIL, Quebec — The Jean Coutu Group posted a boost in third-quarter net profits as revenues decreased largely because of the growth in generic drug prescriptions.
“The results of the third quarter of fiscal 2014 highlight the performance of our organization since the operating income and the profit per share recorded a significant increase in spite of a growing competitive environment and a restrictive regulatory context,” said Francois Coutu, president and CEO. “Our priority over the coming months will be to continue the implementation of dynamic strategic initiatives that will contribute to increase sales, pursue our growth and maintain our leadership.”
During the quarter ended Nov. 30, operating income before amortization rose 3.4%, despite the deflationary impact on pharmacy sales of a strong generic drugs penetration.
Net profit totaled Canadian $62.5 million, or 30 Canadian cents per share, compared with C$56.2 million, or 26 Canadian cents per share, in the year-ago period.
Revenues totaled C$712.5 million compared with C$716.6 million. The company attributed the decrease to the deflationary impact on revenues of the significant volume increase in prescriptions of generic drugs as well as the price reductions of generic drugs.
On a same-store basis, the company’s retail sales slipped 1.3%. Pharmacy same-store sales decreased 1.6% as front-end same-store sales decreased 1.3%.